Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | YL202 |
| Trade Name | |
| Synonyms | YL 202|YL-202|BNT326|BNT-326|BNT 326 |
| Drug Descriptions |
YL202 is an antibody-drug conjugate (ADC) comprising an ERBB3 (HER3)-targeted antibody conjugated to a novel topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 563). |
| DrugClasses | HER3 (ERBB3) Antibody 28 |
| CAS Registry Number | NA |
| NCIT ID | C199281 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BNT327 + YL202 | BNT327 YL202 | 0 | 2 |
| Itraconazole + YL202 | Itraconazole YL202 | 0 | 1 |
| YL202 | YL202 | 0 | 3 |